Independent Non-Employee Director of AbCellera Biologics Picks Up 66% More Stock

Potential AbCellera Biologics Inc. (NASDAQ:ABCL) shareholders may wish to note that the Independent Non-Employee Director, John Montalbano, recently bought US$141k worth of stock, paying US$2.34 for each share. That certainly has us anticipating the best, especially since they thusly increased their own holding by 66%, potentially signalling some real optimism.

Check out our latest analysis for AbCellera Biologics

The Last 12 Months Of Insider Transactions At AbCellera Biologics

In the last twelve months, the biggest single purchase by an insider was when CEO, President & Chairperson Carl Hansen bought US$740k worth of shares at a price of US$2.61 per share. That means that an insider was happy to buy shares at above the current price of US$2.33. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

AbCellera Biologics insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

AbCellera Biologics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Does AbCellera Biologics Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that AbCellera Biologics insiders own 23% of the company, worth about US$157m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Do The AbCellera Biologics Insider Transactions Indicate?

The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Once you factor in the high insider ownership, it certainly seems like insiders are positive about AbCellera Biologics. One for the watchlist, at least! While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 1 warning sign for AbCellera Biologics and we suggest you have a look.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.